Search

Corvus Pharmaceuticals Inc

Cerrado

13.27 0.15

Resumen

Variación precio

24h

Actual

Mínimo

13.02

Máximo

13.36

Métricas clave

By Trading Economics

Ingresos

-1.4M

-14M

BPA

-0.15

Empleados

37

EBITDA

312K

-12M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+138.31% upside

Dividendos

By Acuity

Próximas Ganancias

6 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-261M

1.1B

Apertura anterior

13.12

Cierre anterior

13.27

Corvus Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

31 jul 2026, 23:56 UTC

In after-market trading, Invesco Ltd shares are lower, moving from a high of 0.51% to a low of -0.81%. No specific news was identified.

31 jul 2026, 23:56 UTC

Social Media

Equifax Inc. shares are higher in after-market trading, buoyed by CEO Mark Begor's outlook on strong cash flow and $1.6 billion returned to shareholders.

31 jul 2026, 23:56 UTC

Dutch Bros Inc. shares are lower in after-market trading, fluctuating within a routine range since Friday's close. The price remains stable in its one-month trading range.

31 jul 2026, 23:56 UTC

MannKind Corp shares traded lower in after-market hours, retreating from earlier gains. The stock remains near the lower end of its one-month range.

31 jul 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Welltower and raised its price target to $275. Shares are modestly higher in after-market trading.

31 jul 2026, 23:56 UTC

iShares 1-3 Year Treasury Bond ETF trading roughly flat in after-market hours. Global equity indices are mixed, with U.S. markets lower and others higher.

31 jul 2026, 23:56 UTC

Indie Semiconductor Inc. shares are near unchanged in after-market trading, following a notable decline over the past month and remaining below the 20-day moving average.

31 jul 2026, 23:56 UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

31 jul 2026, 23:56 UTC

ETF Constituents

Vanguard Real Estate ETF trading was roughly flat after hours, with CSGP, VNO, and IIPR contributing negatively while ADC provided a modest positive impact.

31 jul 2026, 23:56 UTC

AeroVironment Inc shares are lower in after-market hours, with no specific news identified. The stock is near the lower end of its one-month range.

31 jul 2026, 23:56 UTC

Transocean Ltd shares are higher in after-market trading, continuing a trend of gains over the past three sessions. No specific news was identified for the move.

31 jul 2026, 23:56 UTC

Comcast shares are higher in after-market trading, showing volatility with no specific news to explain the movement. Broader market trends include gains in the Nikkei 225.

31 jul 2026, 23:56 UTC

Correlated Moves

Texas Instruments Inc. shows little change in after-market trading, reflecting broader weakness in the technology sector amid mixed Asian market performance.

31 jul 2026, 23:56 UTC

Barnes Group Inc. shares declined in after-market trading, showing minor fluctuations without specific news. Asian market results provided broader context for the movement.

31 jul 2026, 23:56 UTC

Diamondback Energy Inc shares are higher in after-market trading, continuing recent upward momentum and reflecting strong investor interest amid no specific news.

31 jul 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

31 jul 2026, 23:56 UTC

Marathon Digital Holdings shares are higher in after-market trading, reflecting routine activity with no specific news identified. The stock remains below its 20-day moving average.

31 jul 2026, 23:56 UTC

MSCI Inc. shares advanced in after-market trading, supported by a rise in the Nikkei 225 Index and renewed interest in AI stocks.

31 jul 2026, 23:56 UTC

Block Inc shares are higher in after-market trading, buoyed by strong earnings from U.S. tech companies that eased concerns about AI infrastructure spending.

31 jul 2026, 23:56 UTC

Correlated Moves

Procter & Gamble Co shares declined in after-market trading, reflecting broader sector trends as Kimberly-Clark Corp also reported a drop.

31 jul 2026, 23:56 UTC

Adobe Inc shares are lower in after-market hours, with no specific news identified. The stock has declined since Friday's close, amid mixed broader market trends.

31 jul 2026, 23:52 UTC

Mexican Inflation Rate Set for Release Amid Mixed Market Sentiment and Global Price Pressures

31 jul 2026, 23:52 UTC

Mexico's Inflation Rate Release on August 7, 2026, Amidst Global Economic Pressures and Mixed Market Sentiment.

31 jul 2026, 23:52 UTC

South Korea's July Exports Expected to Grow 0.59% YoY Amid Cautious Optimism Following Record Highs

31 jul 2026, 23:52 UTC

Rising MBA 30-Year Mortgage Rates Reach Highest Levels Since Last Year, Signaling Caution Among Homebuyers Amid Economic Pressures.

31 jul 2026, 23:51 UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

31 jul 2026, 23:51 UTC

Social Media
Correlated Moves
News

Meta Platforms Inc shares are lower in after-market hours, pressured by broader market weakness and concerns over rising AI spending following a disappointing earnings report.

31 jul 2026, 23:51 UTC

Interactive Brokers Group Inc is lower in after-market trading, reflecting the broader market's significant decline and a position below its 20-day moving average.

31 jul 2026, 23:51 UTC

Solaredge Technologies Inc shares declined in after-hours trading, reflecting broader market trends. No specific company news was identified to explain the movement.

31 jul 2026, 23:51 UTC

Evolent Health Inc shares are higher in after-market hours, rebounding from nine consecutive daily declines despite remaining below their 20-day moving average.

Comparación entre iguales

Cambio de precio

Corvus Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

138.31% repunte

Estimación a 12 Meses

Media 31.6 USD  138.31%

Máximo 40 USD

Mínimo 27 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Corvus Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat